A randomized, double blind, placebo controlled, Proof of Concept (PoC) study to assess the efficacy, safety and tolerability of itepekimab in participants with inadequately controlled chronic rhinosinusitis without nasal polyps

Respiratory tract diseases

Change from baseline in sinus (maxillary, ethmoid) percent opacification volume assessed by CT scan

Change from baseline in the sTSS, Change from baseline in nasal congestion (NC) severity score, Anterior/posterior rhinorrhea severity score, Facial pain/pressure severity score, and Loss of smell severity score using the CRSsNP daily e diary, Change from baseline in SNOT­22 total score, Change from baseline in sinus opacification as measured by the Lund-Mackay (LMK) score and the modified LMK score, Incidence of (treatment-emergent adverse events (TEAEs), treatment-emergent adverse events of special interest (TEAESIs), treatment emergent serious adverse events (TESAEs), and treatment-emergent adverse events (TEAEs) leading to intervention discontinuation, Itepekimab concentration in serum, Incidence of treatment-emergent (TE) anti-itepekimab antibodies responses

No related papers found yet.

Belgium, France, Italy, Poland, Portugal, Romania, Spain